The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study
about
Update on denosumab in the management of postmenopausal osteoporosis: patient preference and adherenceBone strength and management of postmenopausal fracture risk with antiresorptive therapies: considerations for women's health practiceObservations following discontinuation of long-term denosumab therapy.Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension studyRecent advances in the management of osteoporosisAtypical femoral fractures mimicking metastatic lesions in 2 patients taking denosumab.Osteoporosis: a discussion on the past 5 years.Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium.Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis.The Prevention of Medication-related Osteonecrosis of the Jaw.Osteoporosis therapeutics: recent developments at ASBMRDifferential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study.Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis.High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis.Unmet needs and current and future approaches for osteoporotic patients at high risk of hip fracture.Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis.Osteoporosis Therapy: Bone Modeling during Growth and Aging.Comparative effects of denosumab or bisphosphonate treatment on bone mineral density and calcium metabolism in postmenopausal womenSimultaneous bilateral atypical femoral fracture in a patient receiving denosumab: case report and literature review.New anabolic therapies for osteoporosis.Safety issues and adverse reactions with osteoporosis management.Denosumab: an Emerging Therapy in Pediatric Bone Disorders.Treatment of Paget's Disease of Bone with Denosumab: Case Report and Literature Review.A Systematic Review of Treatment Strategies for Degenerative Lumbar Spine Fusion Surgery in Patients With Osteoporosis.Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures.Role of cortical bone in hip fracture.Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study.Remodeling- and Modeling-Based Bone Formation with Teriparatide versus Denosumab: A Longitudinal Analysis from Baseline to 3 Months in the AVA Study.Key Triggers of Osteoclast-Related Diseases and Available Strategies for Targeted Therapies: A Review.Denosumab or oral bisphosphonates in primary osteoporosis: a "real-life" study.Rebound-associated vertebral fractures after discontinuation of denosumab for the treatment of maxillitis.Spanish consensus on treat to target for osteoporosis.Effects of raloxifene and alendronate on non-enzymatic collagen cross-links and bone strength in ovariectomized rabbits in sequential treatments after daily human parathyroid hormone (1-34) administration.Treatment of postmenopausal osteoporosis: a literature-based algorithm for use in the public health care system.Bone Loss After Denosumab: Only Partial Protection with Zoledronate.Multiple Vertebral Osteonecroses (Kümmell's Disease) After 10 Years on Denosumab: Is Osteocyte Apoptosis to Blame?Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension.Denosumab for the Treatment of Mastocytosis-Related Osteoporosis: A Case Series.Effects of Long-term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis.Osteonecrosis of the Jaw (ONJ) in Osteoporosis Patients: Report of Delayed Diagnosis of a Multisite Case and Commentary about Risks Coming from a Restricted ONJ Definition.
P2860
Q26778291-11D91552-6CA4-4A2B-94BA-299EE23FFAD6Q28066185-463ECC5A-EC70-4DF8-9083-87DF49DCE4D5Q33563846-C5DE3A7D-9FB9-45D7-B75D-C0E8D52991B1Q33612987-D8CECC3D-946F-4C90-AA35-94FA6D20FC7CQ33672136-63DC3E5E-9CED-480B-ACE2-984996972F38Q33697117-0EC6D4BC-0634-41AF-BC63-30CA7DFA44F4Q33700265-6259DC10-8E08-4D50-88E0-C0F3A0077646Q33841204-E428E9DD-0F08-4E6C-8586-8D97934A1CB2Q34545263-FEF7F1B1-2172-46F3-AABD-16AEB4CB45D9Q36292333-92EFAB57-9D94-442B-BCB5-4E971481F3EDQ36448678-E5FAEA59-99C2-4DC6-8CD6-796290EDA2E5Q36935525-200A82E4-22C4-4E43-A52B-D52B72D2631FQ37192904-0777858E-024A-409E-90DC-E41D58DBF8BCQ37488814-E8490C2A-D763-4179-9BBA-45C5815DE975Q37639402-76C0E689-9477-490B-BCFA-163C122FADC3Q37661855-03E725C9-D6BD-4454-85F7-3C443DA0EDF7Q37689421-33174469-892A-4EE6-AE92-E8CBE936A277Q37740752-148CFA0D-9FC9-4352-A5B5-960A37BDEE3AQ38616418-C31E08F6-7B2C-4CC8-8CB2-0A2162C2F2EFQ38646406-78E22D51-C9F8-4F2E-8AF3-16B3C9E82106Q38677822-18DA6D8C-3EC0-4440-8B9D-D7E703F79A04Q38712724-19BD994C-8C66-40AC-B2BD-245B8351B6FEQ38837818-9A2E1AF9-6275-432A-BA7A-A74C8D4BC482Q39009669-62B4B2AA-F0F5-46A9-9EDB-D0C4D210B15FQ39013177-9346BC17-EF25-4B02-8B56-F48FB259E396Q39170719-32829F73-B332-4563-AD36-DD6DB51BE4D1Q39296189-C96B23EE-272A-405B-BD76-263B7E5FEC3CQ42696517-C5A56E72-BA17-4CE0-83B2-D35874AE62FAQ47400369-CDC5D101-488C-42F4-8BEB-55989864111AQ47552430-15F91200-B994-4185-9568-258FAF3D2C6EQ47566316-A7D785C5-9F97-44D9-8819-20D61B8FD801Q47596255-C008DFA7-3791-47F3-8AB3-603005B177ACQ47962287-51BB8925-1F7F-4B07-90CD-7579B7932EAFQ47981699-DC2D1DEC-417A-46FA-A9B5-990415C64D7BQ48149601-A0EBA1A8-2F77-45F9-B3FC-68C14A030093Q48365103-BBA1A817-AD21-453A-9F42-9EC7E9B82D42Q50142958-066F2F81-472F-41BC-8DB9-0800B9A13D73Q51272075-B70A5B51-0FD2-418F-82E7-5FACB26E6E89Q52577840-7EC43A9E-B204-4FC1-B69F-A2464CAE7158Q52643968-CF2B3FF0-E7D7-4168-A92C-45D39FDEDF5C
P2860
The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
The effect of 8 or 5 years of ...... om the FREEDOM Extension study
@ast
The effect of 8 or 5 years of ...... om the FREEDOM Extension study
@en
type
label
The effect of 8 or 5 years of ...... om the FREEDOM Extension study
@ast
The effect of 8 or 5 years of ...... om the FREEDOM Extension study
@en
prefLabel
The effect of 8 or 5 years of ...... om the FREEDOM Extension study
@ast
The effect of 8 or 5 years of ...... om the FREEDOM Extension study
@en
P2093
P2860
P1476
The effect of 8 or 5 years of ...... om the FREEDOM Extension study
@en
P2093
C Libanati
C Mautalen
D L Kendler
E Czerwiński
E M Lewiecki
P2860
P2888
P304
P356
10.1007/S00198-015-3234-7
P407
P577
2015-07-23T00:00:00Z